Immunology Weekly News – July 23rd 2025

🧬 Immunology Updates: Crohn’s, Ulcerative Colitis, Atopic Dermatitis, Hidradenitis Suppurativa and More

 

Discover this week’s biggest immunology headlines—from clinical trial results and drug approvals to new treatment guidelines shaping autoimmune care.

🔬 This week’s key stories include:

📈 Sanofi acquires Blueprint Medicines
Sanofi expands its immunology portfolio by adding Ayvakit for systemic mastocytosis and two investigational KIT inhibitors, aiming to boost gross margin immediately and earnings after 2026.

💉 Otsuka licenses CAN10 antibody from Cantargia
The deal brings global rights to a promising IL1RAP-targeting antibody for autoimmune and inflammatory conditions, with a total potential value exceeding six hundred million US dollars.

🥗 ECCO publishes new dietary guidelines for IBD
For the first time, Crohn’s disease and ulcerative colitis patients now have tailored nutrition recommendations, emphasizing access to dietitians and peri-operative care to reduce complications.

🧪 Biocad launches Phase 2 trials in IBD
Over one thousand patients will be enrolled in trials across Russia to evaluate BCD-261. Early results showed a strong safety profile, and the company is investing heavily in the program.

🇨🇦 Mirikizumab approved in Canada for Crohn’s
Health Canada expands the label of Omvoh® to include Crohn’s disease after the VIVID-1 study showed clinical remission in forty-five percent of patients after one year—more than double the placebo rate.

🚫 Novartis discontinues ianalumab for HS
Following disappointing Phase 2 results in hidradenitis suppurativa, development in this indication is halted. Studies continue in other B-cell–driven diseases like Sjögren’s syndrome and ITP.

📘 China updates 2025 atopic dermatitis guidelines
The new guidance emphasizes personalized care, JAK1 inhibitors, and real-world data from the AHEAD registry, with the goal of improving long-term patient outcomes.

💨 UK approves needle-free epinephrine spray
EURneffy becomes the first nasal spray alternative to auto-injectors for anaphylaxis treatment. Approved for adults and children over thirty kilograms, launch is expected in late Q3 2025.

📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on immunology and autoimmune diseases

#Immunology #CrohnsDisease #UlcerativeColitis #AtopicDermatitis #HidradenitisSuppurativa #AutoimmuneDiseases #ClinicalTrials #PharmaNews #Biotech #LucidQuest #HealthcareInnovation #MedicalUpdates